Helps pharmacists map where GLP-1RA and dual incretin therapy now carry disease-specific evidence outside diabetes and how that evidence maps onto evolving guidelines.
Across obesity, cardiovascular disease, heart failure with preserved ejection fraction, chronic kidney disease, metabolic dysfunction-associated steatohepatitis, and even alcohol use disorder, GLP-1 receptor agonist (GLP-1RA) benefit tracks the patient's comorbid disease profile more than any BMI threshold, and pharmacists should frame these agents as indefinite, disease-targeted chronic therapy.
GLP-1RAs and the dual GIP/GLP-1RA tirzepatide have accumulated dedicated randomized outcome evidence spanning obesity, atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and metabolic dysfunction-associated steatohepatitis (MASH). The consistent thread is that these agents deliver benefit organized by comorbid disease rather than weight alone, with cardiovascular and renal signals often emerging before or independent of maximal weight loss.
SELECT (PMID 37952131) established a 20% reduction in major cardiovascular events in non-diabetic patients with obesity and established disease, STEP-HFpEF (PMID 37622681) showed symptom gains several-fold larger than existing HFpEF drugs, FLOW (PMID 38785209) added kidney and mortality protection in diabetic CKD, and the semaglutide MASH trial (PMID 40305708) delivered the first phase 3 fibrosis regression with a GLP-1RA. SURMOUNT-1 (PMID 35658024) pushed weight loss to roughly 21% with tirzepatide, and an exploratory Lancet trial (PMID 42070571) signaled reduced heavy drinking in obesity-comorbid alcohol use disorder.
The inaugural 2025 American Diabetes Association (ADA) Obesity Association pharmacotherapy Standards (PMID 41529914) reorganize medication selection around obesity-related disease and formalize GLP-1RA and dual GIP/GLP-1RA agents as highest-efficacy options for type 2 diabetes (T2D), ASCVD, HFpEF, MASH, and obstructive sleep apnea. FLOW aligns with and extends the Kidney Disease: Improving Global Outcomes (KDIGO) 2024 and ADA-KDIGO 2022 frameworks by supporting GLP-1RAs as an additional CKD pillar, while HFpEF and MASH guidelines still lag: the 2022 ACC/AHA/HFSA HFpEF guidance and current MASH guidance (EASL-EASD-EASO 2024, AASLD 2023) predate or do not yet incorporate these agents, and semaglutide remains off-label for MASH and alcohol use disorder.
| Source | Key finding | Grade / Verdict |
|---|---|---|
|
ADA Standards of Care: Pharmacologic Treatment of Obesity in Adults
Guideline · BMJ Open Diabetes Res Care
guideline backbone Reorganizes obesity pharmacotherapy around comorbid disease and frames GLP-1RA and dual incretin therapy as indefinite, disease-targeted treatment.
|
Highest-efficacy agents cited at 16.2% (tirzepatide) and 11.9% (semaglutide) placebo-subtracted weight reduction | Grade: Moderate Practice-changing |
|
Semaglutide cuts heavy drinking in alcohol use disorder with obesity
Study · Lancet
emerging off-label signal Biomarker-validated but obesity-restricted and hypothesis-generating evidence that semaglutide reduces heavy drinking in comorbid alcohol use disorder.
|
Heavy drinking days fell 13.7 percentage points more than placebo (p=0.0015); NNT 4.3 for WHO risk-level reduction | Grade: Moderate Hypothesis-generating |
|
Semaglutide Cuts Cardiovascular Events in Obesity Without Diabetes
Study · New England Journal of Medicine
pivotal cardiovascular evidence SELECT extends cardiovascular benefit to non-diabetic obesity and underpins FDA approval of semaglutide 2.4 mg for event reduction.
|
20% relative reduction in major cardiovascular events (HR 0.80; 95% CI 0.72-0.90), NNT approximately 67 | Grade: High Practice-changing |
|
Semaglutide Cuts Symptoms and Weight in Obesity-Related HFpEF
Study · New England Journal of Medicine
new indication evidence (HFpEF) STEP-HFpEF establishes semaglutide as the most symptom-effective agent yet studied in obesity-related HFpEF.
|
KCCQ-CSS improved 7.8 points and 6-minute walk distance increased 20.3 m versus placebo; win ratio 1.72 | Grade: High Practice-changing |
|
Tirzepatide Delivers Up to 21% Weight Loss in Obesity
Study · New England Journal of Medicine
highest-efficacy weight evidence SURMOUNT-1 sets the current efficacy ceiling for injectable weight management with the dual GIP/GLP-1RA tirzepatide.
|
Up to approximately 21% mean weight loss at 15 mg; 57% achieved at least 20% reduction | Grade: High Practice-changing |
|
Finerenone Cuts Albuminuria in Type 1 Diabetes with CKD
Study · New England Journal of Medicine
new pillar evidence (CKD) FLOW positions semaglutide as an additional evidence-based CKD pillar layered onto RAS and SGLT2 inhibitor therapy.
|
24% relative reduction in primary kidney outcome (HR 0.76; 95% CI 0.66-0.88), 3-year NNT 20 | Grade: Moderate Hypothesis-generating |
|
Semaglutide 2.4 mg Improves Liver Histology in MASH
Study · New England Journal of Medicine
emerging indication evidence (MASH) First phase 3 GLP-1RA trial to show MASH fibrosis regression, though hard outcomes and FDA approval remain pending.
|
Steatohepatitis resolution with fibrosis reduction in 32.7% versus 16.1% (difference 16.5 percentage points) | Grade: Moderate Practice-changing |
Subscribe to PharmD Signal for the complete practice recommendations on every topic, plus every deep analysis we publish.
Become a Subscriber →